​

Titan Pharmaceuticals (TTNP) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

TTNP Stock Rating

Titan Pharmaceuticals stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (50.00%), 2 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 2 2 Strong Sell Sell Hold Buy Strong Buy

TTNP Price Target Upside V Benchmarks

TypeNameUpside
StockTitan Pharmaceuticals-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$4.48$4.48$4.48
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 24--1--1
Oct, 24--1--1
Sep, 24--1--1
Aug, 24-11--2
Jul, 24-11--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

$-150 $-110 $-70 $-30 $10 $50 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-109.88$-16.68$-15.15$-7.41$-5.23--
Avg Forecast$-125.20$-26.80$-18.20$-16.60$-15.20$-8.60$17.40
High Forecast$-125.20$-26.80$-18.20$-16.60$-15.20$-8.60$17.40
Low Forecast$-125.20$-26.80$-18.20$-16.60$-15.20$-8.60$17.40
Surprise %-12.24%-37.76%-16.76%-55.36%-65.59%--

Revenue Forecast

$0 $8M $16M $24M $32M $40M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$4.84M$1.53M$60.00K$184.00K---
Avg Forecast$3.88M$682.00K$192.00K$11.89M$16.51M$7.05M$35.35M
High Forecast$3.88M$682.00K$192.00K$11.89M$16.51M$7.05M$35.35M
Low Forecast$3.88M$682.00K$192.00K$11.89M$16.51M$7.05M$35.35M
Surprise %24.66%123.75%-68.75%-98.45%---

Net Income Forecast

$-100M $-70M $-40M $-10M $20M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-20.73M$-8.11M$-10.18M$-5.57M$-4.71M--
Avg Forecast$-94.15M$-20.15M$-13.69M$-12.48M$-11.43M$-6.47M$13.08M
High Forecast$-94.15M$-20.15M$-13.69M$-12.48M$-11.43M$-6.47M$13.08M
Low Forecast$-94.15M$-20.15M$-13.69M$-12.48M$-11.43M$-6.47M$13.08M
Surprise %-77.98%-59.74%-25.64%-55.39%-58.83%--

TTNP Forecast FAQ

Is Titan Pharmaceuticals stock a buy?

Titan Pharmaceuticals stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Titan Pharmaceuticals is a favorable investment for most analysts.

What is Titan Pharmaceuticals's price target?

Titan Pharmaceuticals's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $4.48.

How does Titan Pharmaceuticals stock forecast compare to its benchmarks?

Titan Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Titan Pharmaceuticals over the past three months?

  • November 2024: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • October 2024: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2024: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Titan Pharmaceuticals’s EPS forecast?

Titan Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-8.6, marking a 64.44% increase from the reported $-5.23 in 2024. Estimates for the following years are.

What is Titan Pharmaceuticals’s revenue forecast?

Titan Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $7.05M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for.

What is Titan Pharmaceuticals’s net income forecast?

Titan Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-6.467M, representing an 37.42% increase from the reported $-4.706M in 2024. Projections indicate .